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| INTRODUCTION
Type 2 diabetes mellitus (T2DM) is a chronic inflammatory disorder induced by changes in number and/or function of immune cells. 1 Some studies have demonstrated that T cells and inflammation play a critical role in the promoting T2DM. 2, 3 A previous study reported an imbalance of CD4 + T helper (Th) cell subsets such as Th1, Th17 and CD4 + CD25 + regulatory T cells (Treg) in patients with T2DM. 1, 4 It has also been shown that the serum levels of pro-inflammatory T cell cytokines including interleukin (IL)-6, IL-17, interferon (IFN)-γ, and tumour necrosis factor (TNF)-α are increased in T2DM patients. 
| MATERIALS AND METHODS

| Participants
The study participants comprised 20 healthy control subjects (HC, 12 
| Cell isolation
Peripheral whole blood were collected in tubes with EDTA, 16 The stained cells were washed in PBS and analysed using a flow cytometer (Attune NxT, USA) and FLOWJO software V10 (Tree Star, USA). The positivity for all markers was determined based on fluorescence minus one (FMO) or unstained controls. 9 In parallel experiments, PBMCs were stimulated with anti-CD3 and anti-CD28 and cultured for 5 days. The PBMCs culture supernatants were centrifuged/stored at −80°C until IL-2 cytokine measurement.
| Proliferation and suppression assay
| Analyse of pSTAT5
Phosphorylation of STAT5 (pSTAT5) 
| Measurement of IL-2 production
The level of IL-2 of PBMCs supernatants was assessed using an ELISA kit (Invitrogen, USA, Cat no: 88-7025-22) according to the manufacturer's instructions.
| Statistical analyses
Nonparametric statistical tests including the Mann-Whitney U test and Wilcoxon were used for data analyses. The results were stated as median and range (minimum-maximum) values. Statistical analyses were performed using SPSS (version 21 software). Graphs were drawn with GRAPH PAD PRISM (version 6.07). A value of P < 0.05 was considered statistically significant.
| RESULTS
| Frequency of CD4 + T cell subsets in T2DM patients
To determine the frequency of the T cell subsets in T2DM patients and HC, the PBMCs were stained with anti-CD4, anti-CD25 and anti CD45RA antibodies and the cells were analysed using flow cytometry. Figure 1A Figure 3A shows representative plots from a donor with T2DM and one of the healthy control group, demonstrating a strong suppressive ability of Treg Figure 3B ). The % suppression of proliferation was significantly lower in T2DM patients compared with the HCs [56.2% (11.8%-80.2%) vs 72.55% (40.1%-84.6%), P = 0.014] ( Figure 3C ). This result showed that the suppressive capacity of Tregs is reduced in T2DM patients.
| pSTAT5 is decreased in CD4 + T cell subset of individuals with T2DM
For the evaluation of IL-2 signalling pathway in promoting FOXP3 expression in CD4 + T cells, the phosphorylation level of STAT5 was assessed in T2DM patients and HCs. Figure 4A demonstrates Figure 4B ). 
| Cellular levels of FOXP3 is reduced in individuals with T2DM
| No change in the production of IL-2 between the T2DM and HC groups
It has been proven that consumption of IL-2 by Tregs is an important mechanism for the functioning of these cells in peripheral blood. To reveal the mechanisms that underlie the reduced functional ability of the Tregs in T2DM, the production of IL-2 was assessed. For this, PBMCs were stimulated with anti-CD3 and anti-CD28 for 5 days and the level of IL-2 was measured in culture supernatants. Generally, no significant changes were observed in the level of IL-2 between the T2DM patients and HC groups [45 pg/ mL (20.2-53) vs 47 pg/mL (12.5-65.5)] (Figure 6 ). Comparisons of the IL-2 level in unstimulated culture conditions did not reveal any significant differences between the patient and HC groups (data not shown). 32 Based on previous studies, it can be said that reduced functional ability of Treg in T2DM patients may be associated with IR. Nevertheless, there is a need for future studies to help to elucidate this possibility. Future research should focus on determining the origin of the Tregs dysfunction (such as possible defects in signal pathways for FOXP3 including Janus kinases, genetic changes in methylation patterns or polymorphisms in FOXP3/associated gene). By understanding the mechanisms that underlie the Tregs dysfunction in T2DM, it may be possible to identify new therapies for this debilitating disease. T2DM patients is caused by both Treg cells and involves the IL-2 signalling pathway, with pSTAT5 playing a key role in this process. Further studies are needed to further define the Treg dysfunction in T2DM subgroups, with correlations to the clinical parameters.
| DISCUSSION
| CONCLUSION
